Terms: = Uterine cancer AND MAP2K4, MEK4, 6416, P45985, ENSG00000065559, SERK1, JNKK1, MKK4, PRKMK4, MAPKK4, JNKK, SEK1 AND Treatment
3 results:
1. uterine leiomyosarcomas harboring map2k4 gene amplification are sensitive in vivo to PLX8725, a novel map2k4 inhibitor.
McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
[TBL] [Abstract] [Full Text] [Related]
2. Gene Expression Analysis Identifies Novel Targets for Cervical cancer Therapy.
Roszik J; Ring KL; Wani KM; Lazar AJ; Yemelyanova AV; Soliman PT; Frumovitz M; Jazaeri AA
Front Immunol; 2018; 9():2102. PubMed ID: 30283446
[TBL] [Abstract] [Full Text] [Related]
3. c-Jun N-terminal kinase regulates apoptosis in endometrial cancer cells.
Reno EM; Haughian JM; Jackson TA; Thorne AM; Bradford AP
Apoptosis; 2009 Jun; 14(6):809-20. PubMed ID: 19424800
[TBL] [Abstract] [Full Text] [Related]
